Prognostic Hemostasis Biomarkers in Acute Ischemic Stroke

Area of Science:

• Neurology
• Hematology
• Biomarker Discovery

Background:

• Predicting clinical outcomes in acute ischemic stroke (AIS) is challenging.
• Coagulation factor imbalances may influence AIS progression and prognosis.
• Hemostasis biomarkers are potential indicators of AIS outcomes.

Purpose of the Study:

• To systematically review the literature on hemostasis biomarkers and their association with poor clinical outcome in AIS.
• To assess the predictive value of hemostasis biomarkers for AIS prognosis.

Main Methods:

• Systematic literature search across major databases (Embase, Medline, Cochrane, Web of Science, Google Scholar).
• Inclusion criteria: studies reporting hemostasis biomarkers and clinical outcome in AIS, blood samples within 72 hours of onset, and validated disability scores (Barthel Index, modified Rankin Scale).
• Methodological quality assessed using an adapted QUADAS tool.

Main Results:

• 41 studies reporting 37 different hemostasis biomarkers were included.
• No single hemostasis biomarker demonstrated effectiveness in predicting poor clinical outcome in AIS patients.
• Some biomarkers exhibited promising results requiring further investigation.

Conclusions:

• Current literature does not support definitive recommendations for hemostasis biomarkers in predicting AIS clinical outcome.
• Further large-scale validation studies with rigorous designs are needed for promising biomarkers.